Less than an hour after a U.S. jury convicted Martin Shkreli of securities fraud, the so-called "Pharma Bro" was back at his New York City apartment doing what comes naturally: trash talking in a live-stream on YouTube. The brash former pharmaceutical CEO, who's still out ...
Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines. Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its blood-pressure treatments Benicar, ...
Closing arguments got underway Thursday in the securities fraud trial of Martin Shkreli, a former hedge fund manager and pharmaceutical executive label "The Most Hated Man in America." The 34-year-old, who hunched over in his chair and fiddled with his hair, risks being jailed for ...
President Donald Trump has pledged to reverse what he describes as "astronomical" drug prices in the United States. Thousands of kilometers away, Japan, long a profit sanctuary for multinational pharmaceutical companies, is taking a similar tack. Somewhere in the ballpark of ¥10 trillion is spent ...
A group of Australian schoolchildren working on a shoestring budget have recreated the HIV drug whose price was controversially jacked up 5,000 percent by a former hedge fund manager. U.S. drug company chief Martin Shkreli became a global figure of hate after buying the rights ...
Daiichi Sankyo Co. said Friday that an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the drugmaker around ¥56.2 billion ($524 million) for concealing critical information. Daiichi Sankyo sold its stake in Ranbaxy Laboratories Ltd. to ...
When two of the world's biggest pharmaceutical companies announced a tie-up in Japan, its $78 billion drug industry took note. In November, the nation's largest drugmaker, Takeda Pharmaceutical Co., said it'd separate its off-patent products and share its extensive domestic distribution network with Israel's Teva ...
This year's Japanese stock rally has a surprise leader: pharmaceutical companies, which tend to lag behind the market when it gains. Drugmakers soared 22 percent, the most among the 33 industry groups on the benchmark Topix index, compared with a 10 percent gain for the ...
Takeda Pharmaceutical Co. has named Christophe Weber chief executive officer as part of a planned succession that makes the French national one of the few international executives to lead a Japanese company. Weber, currently the chief operating officer, takes the new position effective April 1, ...
Daiichi Sankyo Co. risks losing a slice of revenue to generic-medicine competition next year. Now, the drugmaker's plans to fill the gap have hit a roadblock and investors worry that growth may flounder. The Tokyo-based company's best-selling medicine is set to lose patent protection in ...
The French National Institute of Health and Medical Research said Thursday that clinical trials of the Japanese influenza drug Avigan Tablet, also known as Favipiravir, are showing encouraging results on Ebola patients in Guinea. The office of the French president was informed of the news ...
Vitamin and mineral supplements are big business in Japan, but are they really any use?
